Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899126 · ClinicalTrials.gov registry record · Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 686
- Enrollment target
- 20
- Study locations
NCT06899126 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 686 participants, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT06899126, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 686 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG Pemetrexed
- DRUG Chemotherapy
- DRUG Trastuzumab Deruxtecan
Study Locations (20)
California
- Orange Coast Memorial Medical Center Fountain Valley - Fountain Valley
- California Research Institute - Los Angeles
- Los Angeles Cancer Network (LACN) - Los Angeles
- Providence Medical Foundation - Santa Rosa
Florida
- Bay Pines VA Healthcare System - Bay Pines
- Holy Cross Hospital - Fort Lauderdale
- Mid-Florida Hematology & Oncology Centers, P.A. - Orange City
- BRCR Global Plantation - Plantation
Texas
- University of Texas M. D. Anderson Cancer Center - Houston
- Lumi Research - Kingwood
Other
- CINME - Centro De Investigaciones Metabolicas - Buenos Aires
- Instituto Argentino de Diagnostico y Tratamiento - Buenos Aires
Alaska
- Alaska Oncology & Hematology, LLC - Anchorage
Illinois
- Hope and Healing Cancer Services - Hinsdale
Montana
- Logan Health Research - Kalispell
New York
- Clinical Research Alliance - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 686 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2032-07-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06899126
The ClinicalTrials.gov registry entry for NCT06899126 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 686 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which pembrolizumab is the first listed.
NCT06899126 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06899126 about?
NCT06899126 is a clinical study titled "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer". This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic n...
What is the current status of trial NCT06899126?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 686 participants. The study started on 2025-10-24. Estimated completion is 2032-07-05.
What conditions does trial NCT06899126 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06899126?
The interventions under investigation include: pembrolizumab (DRUG), Pemetrexed (DRUG), Chemotherapy (DRUG), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06899126?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899126 being conducted?
This trial has 20 study locations across Alaska, California, Florida, Illinois, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.